Literature DB >> 2777838

Complications of heparin therapy after total joint arthroplasty.

B M Patterson1, R Marchand, C Ranawat.   

Abstract

The cases of 112 patients who were treated intravenously with heparin for thromboembolic disease after total joint arthroplasty were reviewed. The over-all frequency of bleeding complications that were associated with therapy with heparin was approximately 30 per cent. In patients who were treated within six days after total joint replacement, the frequency of bleeding complications was 45 per cent. The prevalence of bleeding problems declined to 15 per cent in patients who were treated more than one week after arthroplasty. In roughly 35 per cent of the patients, therapy with heparin had to be discontinued because of complications. Thrombocytopenia developed in fewer than 5 per cent of the patients. It was concluded that anticoagulation therapy with heparin for clinically unimportant thromboembolic problems in the immediate postoperative period is not justified.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2777838

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  10 in total

1.  Overdiagnosis of pulmonary embolism: evaluation of a hypoxia algorithm designed to avoid this catastrophic problem.

Authors:  Brian S Winters; Mark Solarz; Christina L Jacovides; James J Purtill; Richard H Rothman; Javad Parvizi
Journal:  Clin Orthop Relat Res       Date:  2012-02       Impact factor: 4.176

2.  Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  James D Douketis; Alex C Spyropoulos; Frederick A Spencer; Michael Mayr; Amir K Jaffer; Mark H Eckman; Andrew S Dunn; Regina Kunz
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Triple Antithrombotic Therapy and Outcomes in Post-PCI Patients Undergoing Non-cardiac Surgery.

Authors:  Javier A Valle; Laura Graham; Aerin DeRussy; Kamal Itani; Mary T Hawn; Thomas M Maddox
Journal:  World J Surg       Date:  2017-02       Impact factor: 3.352

Review 4.  Economics of thromboprophylaxis in total hip replacement surgery.

Authors:  J Harrison; D J Warwick; J Coast
Journal:  Pharmacoeconomics       Date:  1997-07       Impact factor: 4.981

5.  High incidence of complications from enoxaparin treatment after arthroplasty.

Authors:  Andrew S Neviaser; Charles Chang; Stephen Lyman; Alejandro Gonzales Della Valle; Steven B Haas
Journal:  Clin Orthop Relat Res       Date:  2009-08-11       Impact factor: 4.176

6.  The role of ultrasonography in thromboembolic disease management in the orthopaedic patient.

Authors:  W J Ciccone; J S Reid; V D Pellegrini
Journal:  Iowa Orthop J       Date:  1999

7.  Case report: perioperative use of protein c concentrate for protein C deficiency in THA.

Authors:  Savyasachi C Thakkar; Michael B Streiff; Duane F Bruley; Simon C Mears
Journal:  Clin Orthop Relat Res       Date:  2009-12-10       Impact factor: 4.176

8.  Can Early Rehabilitation after Total Hip Arthroplasty Reduce Its Major Complications and Medical Expenses? Report from a Nationally Representative Cohort.

Authors:  Daniel Chiung-Jui Su; Kuo-Shu Yuan; Shih-Feng Weng; Rong-Bin Hong; Ming-Ping Wu; Hing-Man Wu; Willy Chou
Journal:  Biomed Res Int       Date:  2015-06-04       Impact factor: 3.411

9.  Incidence of venous thromboembolism using 64 channel multidetector row computed tomography-indirect venography and anti-coagulation therapy after total knee arthroplasty in Korea.

Authors:  Kyung-Hyun Park; Sang-Ho Cheon; Ji-Ho Lee; Hee-Soo Kyung
Journal:  Knee Surg Relat Res       Date:  2012-02-28

10.  Bridging therapy for oral anticoagulation increases the risk for bleeding-related complications in total joint arthroplasty.

Authors:  Martijn Haighton; Diederik H R Kempen; Nienke Wolterbeek; Louis N Marting; Martijn van Dijk; Remmelt M R Veen
Journal:  J Orthop Surg Res       Date:  2015-09-17       Impact factor: 2.359

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.